Talk:Pitolisant
| This is the talk page for discussing improvements to the Pitolisant article. This is not a forum for general discussion of the article's subject. |
Article policies
|
| Find medical sources: Source guidelines · PubMed · Cochrane · DOAJ · Gale · OpenMD · ScienceDirect · Springer · Trip · Wiley · TWL |
 | This article is rated Start-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | ||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||
 | Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Pitolisant.
|
Bad citation practice
editIn "History", Reference 5 is cited at the end of almost every sentence. This is bad citing practice and the text reads very unscientific overall.
Conflicting sources for pharmacology of pitolisant
editThe inverse agonistic property of pitolisant at h3 is well established, but secondary actions at sigma, d3, and 5ht2a are less extensively characterised. I have cited an FDA review as opposed to individual primary studies as there are some conflicting results in the primary literature. The FDA review does not state its rationale for the designation of pitolisant as an antagonist to all of the aforementioned sites. I'm not qualified to understand how the reviewers may have weighed the results of these studies. If someone here is, please take a look at the cited reviews and edit my content to be less vague. I've avoided presenting information beyond my understanding.
Reviews: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211150Orig1s000OtherR.pdf and https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211150Orig1s000MedR.pdf Oro Temp (talk) 19:57, 28 September 2024 (UTC)